EHC Launches New Rehabilitation Hospital in Lake Worth to Address Growing Need
New Facility Opening: Encompass Health Corporation has opened the Encompass Health Rehabilitation Hospital of Lake Worth in Florida, featuring 50 beds and advanced rehabilitation technologies to assist patients recovering from complex medical issues.
Comprehensive Care Model: The hospital employs an interdisciplinary care model, providing tailored treatment plans that include a minimum of three hours of therapy five days a week, 24/7 nursing care, and physician oversight to enhance patient mobility and quality of life.
Expansion Plans: EHC is expanding its presence in Florida, marking its 26th location in the state, and plans to open seven new hospitals and add beds to existing facilities in 2025, reflecting the growing demand for rehabilitation services.
Financial Performance: EHC's net operating revenues increased by 10.6% year-over-year in the first nine months of 2025, with its stock gaining 23.3% year-to-date, outperforming the industry average growth of 10.3%.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on BTSG
About BTSG
About the author

Prestige Consumer Acquires Pillar5 Pharma to Expand Eye Care Product Line
- E-Commerce Growth: Prestige Consumer reported double-digit consumption growth in e-commerce channels, with online sales representing up to 20% of total sales in fiscal 2025, reflecting the success of its digital strategies and enhancing market competitiveness.
- Acquisition Fuels Growth: The company announced the acquisition of Pillar5 Pharma, expected to close in Q3 of fiscal 2026, which will enhance supply capabilities in the eye care category, securing near-term supply and expanding long-term production capacity, thereby diversifying its product portfolio.
- Stable Solvency: As of the end of Q2 fiscal 2026, Prestige Consumer reported no short-term debt and cash equivalents of $119 million, indicating a robust financial position that helps mitigate risks from economic fluctuations.
- Cost Pressure Challenges: Despite facing approximately $5 million in tariff costs and supply chain disruptions, Prestige Consumer is proactively implementing cost-saving measures and tactical pricing strategies to offset these impacts, ensuring sustained profitability.

Insulet's Omnipod 5 Platform Achieves Over $200 Million in International Revenue
- Market Share Growth: Insulet's Omnipod 5 platform achieved over $200 million in international revenue for the first time in Q3 2025, driven by rapid product adoption and increasing market demand, significantly enhancing the company's competitive position.
- Surge in U.S. Revenue: U.S. Omnipod revenues grew by 25.6% year-over-year, exceeding the high end of the company's guidance, indicating sustained strong demand for Omnipod 5 among both Type 1 and Type 2 diabetes patients, further expanding the company's market share.
- Strong Financial Health: As of Q3 2025, Insulet reported cash and cash equivalents of $757.4 million with current debt of $80 million, showcasing robust financial stability amid economic uncertainty, which supports future expansion and investment.
- Ongoing Strategic Investments: Insulet is increasing investments in platform innovation, including sensor integrations with Dexcom and Abbott, which are expected to further enhance its technological advantage and drive growth in global markets.






